Change #10 of 10 — RA / CMC

Your product's supply status now depends on its ERA.

Article 51.1(f) allows regulators to restrict PMT, PBT, vPvB and vPvM substances to prescription-only on environmental grounds alone — regardless of clinical risk. Environmental hazard is now a supply classification trigger.

Screen PMT/PBT riskSee how Regunaut helps
The commercial impact

An environmental hazard conclusion is now a commercial event

For OTC products, Art. 51.1(f) reclassification eliminates an entire sales channel. Proactive screening is non-optional.

4

Hazard categories that can trigger Rx reclassification: PBT, vPvB, PMT, vPvM

SourceArt. 51.1(f)

200+

Substances under EMA ERA Monograph programme — active environmental screening

SourceEMA ERA programme

~30%

Of OTC portfolio substances estimated at environmental risk — varies by therapeutic area

SourceIndustry estimate
What's actually changing

Environmental prescription: old vs new

Article 51.1(f) introduces Rx restriction based on environmental hazard — a category that doesn't exist in Directive 2001/83/EC.

Workbench
+ New Task
Quick Tasks/Environmental prescription — current vs new directive

The EMA just published a monograph classifying our OTC antihistamine's active substance as PMT. Can regulators make us go Rx on environmental grounds alone?

RegIntel
RegIntel12:39
142.00s272 sources90% confidence2 warnings
2 warnings

Here's the obligation delta for Environmental prescription. The new EU Pharmaceutical Directive replaces Directive 2001/83/EC[1][2] — below is what changes, row by row.

Current vs. new directive4 rows
Current — 2001/83/EC
New directive — from ~mid-2028
Rx classification basis
Current

Clinical risk only: safety, narrow therapeutic index, misuse potential. Environmental profile not a factor.

New directive

Environmental hazard (PMT/PBT/vPvB/vPvM) is sufficient basis for Rx — independent of clinical risk. OTC products can be reclassified.[3][4]

Who triggers reclassification
Current

No mechanism linking environment to supply classification.

New directive

Competent authority or EMA may require Rx via variation. MAH may self-initiate. EMA ERA Monograph conclusions are the most likely trigger.[5]

ERA interaction
Current

ERA required since 2005 but rarely enforced for hazard-based supply decisions.

New directive

ERA hazard conclusion feeds directly into Art. 51.1(f) classification review. ERA quality now has commercial consequences.[6]

Affected product types
Current

Environmental hazard not linked to supply status.

New directive

Any product — including established OTC brands — containing a substance meeting hazard criteria.[7][8]

⚠Dates reflect the political agreement text; final deadlines depend on entry into force and the transition period for each obligation.

Synthesised from 18 citations across 272 regulatory sources.

Book a 15-minute live walkthrough of the Workbench

Book a demo
Where teams fall short

Three ERA blind spots with commercial consequences

Most teams treat ERA as a scientific exercise disconnected from commercial strategy. Art. 51.1(f) breaks that assumption.

SU

Substance hazard mapping

No PMT/PBT/vPvB/vPvM screening

EM

EMA ERA Monograph programme

No monograph monitoring

Regunaut

The environmental-Rx radar

Spot reclassification risk before regulators flag it.

How Regunaut solves it

Five steps to environmental Rx readiness

From hazard screening to commercial contingency — built to stay ahead of Art. 51.1(f).

Screens every active substance against PMT, PBT, vPvB and vPvM criteria. Outputs per-product reclassification exposure scores with data source documentation.

  • Four hazard category screening per substance
  • Per-product reclassification exposure scoring
  • OTC revenue impact flagging
  • Portfolio heatmap by therapeutic area
Industry evidence

Environmental hazard is now a commercial event

For products with OTC revenue, reclassification under Art. 51.1(f) isn't just regulatory — it eliminates a sales channel.

OTC

Reclassification to Rx removes pharmacy shelf access entirely — immediate revenue consequence for established brands

200+

Active ERA Monograph assessments — every PBT/PMT conclusion is a potential Art. 51.1(f) trigger

EMA ERA programme

Early

ERA updates during consultation can influence hazard conclusions — teams who find out after publication don't get this window

“We had three OTC products containing a substance on the EMA ERA priority list. We only found out because our regulatory director happened to see the monograph publication. There was no system tracking it.”

Head of Regulatory Affairs, Mid-size European Pharma
Common questions

Environmental prescription: what teams ask most

Screen your portfolio for environmental Rx risk

Know your Art. 51.1(f) exposure before regulators act — particularly for OTC products with significant commercial revenue.

Run the PMT/PBT risk screen

Map every active substance against EU environmental hazard criteria across your portfolio.

Screen PMT/PBT risk

Back to directive hub

Environmental prescription is the tenth of ten major changes. See the full picture on the hub.

View all 10 changes
10 / 10